TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01337323

Intervention type: DRUG
Intervention: Fluticasone furoate nasal spray
Description: fluticasone furorate intranasal steroid spray
Study: NCT03737266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sonographically assisted breast surgery
Description: Sonography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonographically assisted breast surgery
Description: Sonography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional breast surgery
Description: Conventional

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional breast surgery
Description: Conventional
Study: NCT00926640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: 6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: 6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: 6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 cycles at 60mg/m2 IV on day 2
Study: NCT04514172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The protocol will be performed without exoskeleton
Description: The protocol will be performed without exoskeleton
Study: NCT02901483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP503
Description: PEP503 will be administered by intratumoral route as slow injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 or tri-weekly 100 mg/m2, depending on which dose level patients are in, with a minimum of accumulated 200 mg/m2 during the 7\~8 weeks' radiation period.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7\~8 weeks.
Study: NCT01691547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC /VI
Description: Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC
Description: Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI
Description: Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF
Description: Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
Study: NCT04241887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic paravertebral blockade
Description: Anesthesia was performed under the ultrasound guidance: the Th8 spinous process was identified, then a probe was moved lateral to medial until two adjacent transverse processes and the pleura were visible. After anaesthetising the skin with 2ml of 1% lignocaine (Lignocainum hydrochlorici, WZF 1%), the Touhy needle 22G (Smith Medical)was introduced under the real time guidance. Once in the paravertebral space, 20ml of 0,25% bupivacaine (Bupivacainum hydrochloricum WZF 0,5%, Polfa Warsaw SA) was injected with an end point of a characteristic pleural displacement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthesia
Description: Local infiltration anaesthesia with 0.5% lignocaine 5ml (Lignocainum hydrochlorici, WZF 1%) was applied to the skin and the potential needle path of ablation.
Study: NCT03880825

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin 500 mg Oral Tablet
Description: single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin 500 mg Oral Tablet
Description: single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Levoketoconazole 150 - 600 mg (BID)
Description: escalating dose from 150 mg to 600 mg (BID)

Intervention type: DRUG
Group type: OTHER
Intervention: Levoketoconazole 150 - 600 mg (BID)
Description: escalating dose from 150 mg to 600 mg (BID)
Study: NCT04865614

Intervention type: DRUG
Intervention: Etomidate
Description: Use of etomidate

Intervention type: DRUG
Intervention: Sevoflurane
Description: Use of sevoflurane
Study: NCT03796208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC)
Description: Women enrolled in the intervention group will receive TAU plus B-EPIC, which includes four core components: 1) Individualized tobacco treatment plus supplemental counseling, 2) Biomarker validation and feedback, 3) Change in maternal thought process and adoption of healthy behavior (e.g. exercise, based on PI framework), and 4) Pharmacotherapy as needed (see Table 3 for a summary of the study design). The initial assessment for this intervention takes 60 minutes, with follow-up sessions typically lasting 15-20 minutes. All sessions occur prior to or after pre-scheduled perinatal appointments. The intervention will be led by a certified tobacco treatment specialist (CTTS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Women enrolled in the control group are informed of the risks of tobacco use and benefits of quitting using the ACOG 5'A's approach by their healthcare provider. This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The five steps of the ACOG recommendation are: 1.) Ask about tobacco use, 2.) Advise to quit, 3.) Assess willingness to make a quit attempt, 4.) Assist in quit attempt, and 5.) Arrange follow-up. The provider may also talk to the participant about nicotine replacement therapy.
Study: NCT00953511

Intervention type: GENETIC
Group type: OTHER
Intervention: ERCC1 pathways analysis
Description: The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
Study: NCT03271918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Study: NCT01161628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
Study: NCT04363710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Calorie Diet
Description: 800-1000 Kcal/day
Study: NCT02383407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Deep Brain Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Deep Brain Stimulation
Study: NCT05076136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional treatment
Description: In reginal treatment patients were given physiotherapy exercises and manual therapies on hip joint as well as on surrounding areas of hip joint such as lumber area and sacroiliac joint.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy treatment
Description: In this treatment patients were given just hip joint mobilizations and quadriceps and hamstrings stretching.
Study: NCT01975636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2609
Description: Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
Study: NCT02860299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citrate 4%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Study: NCT04865510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional citrate anticoagulation
Description: The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Regional citrate anticoagulation
Description: The investigators collected patient's plasma at study start (day 0) and at day 3, 5, 7, 14, 28) .Samples were used to measure inflammatory markers (Il 6, IL 8, IL 10 and TNFα) .~. Markers of dialysis efficiency (BUN, creatinine) and other parameters related to AKI (acid base status, calcium, phosphorus, hemoglobin). The recorded variables also included adverse events, dialysis clotting, hemodynamic status, duration of mechanical ventilation, inotropic support. The hemodynamic parameters were monitored by EV 1000 clinical platform .The investigators measured cardiac performance data, which includes cardiac output (CO), cardiac index (CI), stroke volume (SV), and stroke volume indexes (SVI). Moreover, it also provides information about systemic vascular resistance (SVR). Thus, patient hemodynamic parameters as mentioned above were measured at the following 6 time-point: after the initiation of CRRT (T1), every 6 hours later for 24 hours (T2, T3, T4, T5), and at hour-72 (T6).
Study: NCT03185702

Intervention type: GENETIC
Intervention: Research genetic tests
Description: DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells

Intervention type: GENETIC
Intervention: Research genetic tests
Description: DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells
Study: NCT03536702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Writing Workshop
Description: This group will participate in a writing workshop in group sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Independent Writing - Control Group
Description: This group will receive a book for a self writing session.
Study: NCT02724293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabaline 300 mg once.
Description: patients received pregabaline 300 mg 2 hours pre-operatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabaline 300 mg twice.
Description: patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabaline 600 mg once.
Description: patients received pregabaline 600 mg 2 hours pre-operatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients received placebo
Study: NCT01540812

Intervention type: DRUG
Intervention: Vincristine in induction

Intervention type: DRUG
Intervention: Daunorubicin in induction

Intervention type: DRUG
Intervention: Prednisone in induction

Intervention type: DRUG
Intervention: Metotrexato in induction

Intervention type: DRUG
Intervention: Cytarabine in induction

Intervention type: DRUG
Intervention: Hydrocortisone in induction

Intervention type: DRUG
Intervention: Idarubicin in induction-2

Intervention type: DRUG
Intervention: Fludarabine in induction-2

Intervention type: DRUG
Intervention: Ara-C in induction-2

Intervention type: DRUG
Intervention: G-CSF in induction-2

Intervention type: DRUG
Intervention: Dexamethasone in consolidation-1

Intervention type: DRUG
Intervention: Vincristrine in consolidation-1

Intervention type: DRUG
Intervention: Metotrexato in consolidation-1

Intervention type: DRUG
Intervention: PEG-ASP in consolidation-1

Intervention type: DRUG
Intervention: Dexamethasone in consolidation-2

Intervention type: DRUG
Intervention: ARA-C in consolidation-2

Intervention type: DRUG
Intervention: PEG-ASP in consolidation-2

Intervention type: DRUG
Intervention: Dexamethasone in consolidation-3

Intervention type: DRUG
Intervention: Vincristine in consolidation-3

Intervention type: DRUG
Intervention: Metotrexato in consolidation-3

Intervention type: DRUG
Intervention: PEG-ASP in consolidation-3

Intervention type: PROCEDURE
Intervention: allogeneic HSCT

Intervention type: PROCEDURE
Intervention: Allo HSCT with reduced-intensity conditioning
Study: NCT00926640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 cycles at 60mg/m2 IV on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 cycles at 60mg/m2 IV on day 2
Study: NCT01493999

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel reloading
Description: Up to three times 600 mg clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 60 mg prasugrel in patients with HPR
Study: NCT04254562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Meetings with a Supported Employment/Supported Education Specialist
Description: Participants will receive intervention for 12 months which includes weekly meetings with a Supported Employment/Supported Education Specialist (HYPE Specialist). During the weekly meetings, the HYPE Specialist will review each participant's education and employment goals, and deliver individualized support relevant to those goals which include use of structured HYPE tools and worksheets as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Skill and Strategy Training (FSST)
Description: Participants receive a 12 week Focused Skill and Strategy Training (FSST), a structured cognitive remediation intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Services as Usual
Description: One hour meetings every semester to review individual academic needs and review list of available on campus resources to best meet the student's needs.
Study: NCT01825317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroAD
Description: synchronized TMS+COGNITIVE TRAINING

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
Study: NCT03002922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Sunscreen formula Y65-158
Study: NCT02725008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
Study: NCT01652859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmBisome
Study: NCT00519285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for aflibercept)
Description: Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or Prednisolone
Description: Marketed formulation~5 mg twice daily PO from day 1 continuously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone or Prednisolone
Description: Marketed formulation~5 mg twice daily PO from day 1 continuously
Study: NCT03443011

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose CT without intravenous contrast
Description: participants will receive an extra radiation dosage of about 3 milli Sievert (mSv) depending on patients height and weight. This is the radiation amount from the low dose CT protocol without intravenous contrast.
Study: NCT01222078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: otelixizumab
Description: Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
Study: NCT03447574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ethanol dilution
Description: Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ethanol dilution
Description: Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
Study: NCT01438515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600mg po once daily x 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100mg po twice daily x 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2% mupirocin ointment
Description: \~ 1cm applied to the anterior nares twice daily for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment
Description: \~ 1cm applied to the anterior nares twice daily for 7 days
Study: NCT00926640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 6 cycles 80 mg/m2 IV daily X3 beginning day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 6 cycles 80 mg/m2 IV daily X3 beginning day 2.
Study: NCT01438515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4% chlorhexidine gluconate
Description: Daily full body wash (including hair) for 7 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Description: Daily full body wash (including hair) for 7 days
Study: NCT02175745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoro-dihydroxyphenylalanine
Description: Administered intravenously (IV)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: Component of an 18F-FDOPA PET/CT or PET/MRI scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Description: Component of an 18F-FDOPA PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Component of an 18F-FDOPA PET/MRI
Study: NCT00926640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 6 cycles 80 mg/m2 IV daily X3 beginning day 2.
Study: NCT00865241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study: NCT04774276

Intervention type: OTHER
Intervention: cardiac rehabilitation protocol without occupational therapist
Description: cardiac rehabilitation protocol without occupational therapist will be performed (usual practice before January 2021).

Intervention type: OTHER
Intervention: cardiac rehabilitation protocol with occupational therapist
Description: This intervention (occupational therapist) have been added since 2021 for all patients who need a cardiac rehabilitation protocol.~Occupational therapy is scheduled with sessions 3 times a week for 1 month.
Study: NCT01968512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Same character of Transcranial Direct Current Stimulation but without current
Study: NCT04659902

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein form
Description: Protein form and absence or presence of calcium manipulated

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein form
Description: Protein form and absence or presence of calcium manipulated

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein form
Description: Protein form and absence or presence of calcium manipulated

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein form
Description: Protein form and absence or presence of calcium manipulated